Open an account

Harrow

HROW · NASDAQ

$28.07+$0.39 (+1.41%)TodayMarket closed ·
Prev close $27.68

About HROW

Harrow, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 373 full-time employees. The company went IPO on 2013-02-08. The company offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. The company owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in the United States, all of which are marketed under the Harrow name. The company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. The company owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, FLAREX, NATACYN, BYQLOVI and others. Its development-stage programs include MELT-300, H-N08, CR-01, and MELT-210. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.

Employees
373
Headquarters
Nashville, Tennessee
Listed
Feb 8, 2013
Sector
Health Care
Industry
Pharmaceuticals
Website
harrow.com

HROW key statistics

Market cap
1.04B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
581.31K
Volume
525.49K
Open price
$27.70
High today
$29.25
Low today
$27.70
52 Week high
$54.85
52 Week low
$26.96

Harrow (HROW) at a glance

As of Oct 20, 2026, Harrow (HROW) shares are priced at $28.07, giving the company a market cap of 1.04B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $27.70 and $29.25. The current price is 1.3% above the day's low and 4.0% below its high.

Volume so far is 525.49K shares, in line with the average of 581.31K shares a day.

Over the past year Harrow has ranged from $26.96 to $54.85, and now sits 4% of the way up that range.

Harrow met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.46 per share against an estimate of -$0.1836.

The average analyst price target is $64.26, 128.9% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $64.26
Low
$45.45
Now
$28.07
High
$92.40

HROW earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 937.7% on average.

  1. Q3 FY24: reported -$0.12 per share against an estimate of -$0.0528
  2. Q4 FY24: reported $0.24 per share against an estimate of $0.0753
  3. Q1 FY25: reported -$0.50 per share against an estimate of -$0.0467
  4. Q2 FY25: reported $0.13 per share against an estimate of $0.0074
  5. Q3 FY25: reported $0.22 per share against an estimate of $0.2687
  6. Q4 FY25: reported $0.17 per share against an estimate of $0.3761
  7. Q1 FY26: reported -$0.74 per share against an estimate of -$0.4095
  8. Q2 FY26: reported -$0.46 per share against an estimate of -$0.1836

HROW news

  • Chandrima Sanyal

    Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach

  • Vandana Singh

    Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half

  • Vandana Singh

    Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook

  • Press releaseBusiness Wire

    Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow

  • Vandana Singh

    Harrow Adds Another Piece To Ophthalmology Strategy

  • Press releaseGlobe Newswire

    HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Transcript: Harrow Q1 2026 Earnings Conference Call

Similar companies

Companies in the same industry as Harrow

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.